thiazoles has been researched along with pomalidomide in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Orlowski, RZ | 1 |
| Bolomsky, A; Ludwig, H; Schlangen, K; Schreiner, W; Zojer, N | 1 |
1 review(s) available for thiazoles and pomalidomide
| Article | Year |
|---|---|
Novel agents for multiple myeloma to overcome resistance in phase III clinical trials.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Clinical Trials, Phase III as Topic; Disease-Free Survival; Drug Resistance, Neoplasm; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Immunologic Factors; Indoles; Multiple Myeloma; Oligopeptides; Panobinostat; Phosphorylcholine; Piperidines; Proteasome Inhibitors; Pyridines; Remission Induction; Thalidomide; Thiazoles; Treatment Outcome; Vorinostat | 2013 |
1 other study(ies) available for thiazoles and pomalidomide
| Article | Year |
|---|---|
Targeting of BMI-1 with PTC-209 shows potent anti-myeloma activity and impairs the tumour microenvironment.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cells, Cultured; Dexamethasone; Drug Synergism; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds, 2-Ring; Human Umbilical Vein Endothelial Cells; Humans; Multiple Myeloma; Neovascularization, Physiologic; Oligopeptides; Osteogenesis; Polycomb Repressive Complex 1; Reverse Transcriptase Polymerase Chain Reaction; Thalidomide; Thiazoles; Tumor Microenvironment | 2016 |